Global Von Willebrand Disease Treatment Market: Industry Analysis and Forecast (2020-2026) By Treatment Type, Route of Administration and Region

Global Von Willebrand Disease Treatment Market is expected to reach $XX Mn by 2026 from $XX Mn in 2019, at a CAGR of 7.1% during forecast period.

Global Von Willebrand Disease Treatment Market Overview:

Von Willebrand Disease (vWD) is a frequent bleeding illness characterised by a deficiency or absence of von Willebrand factor (VWF), a clotting factor that aids in blood coagulation. Willebrand factor (VWF) deficiency causes severe bleeding. Type 1 vWD, Type 2 vWD, Type 3 vWD, and Acquired vWD are the four types of vWD.

Global Von Willebrand Disease Treatment Market Dynamics:

Rising prevalence of Von Willebrand Disease is boosting the market growth

The global demand for the market has increased as governments throughout the world have become more aware of the von Willebrand treatment. The treatment for this condition varies from country to country. One of the primary factors projected to drive the growth of the acquired bleeding disorders treatment market is the rising prevalence of bleeding disorders. Another key element that may contribute to the growth of the acquired bleeding disorders treatment market is increased knowledge about genetic illnesses. Von Willebrand disease is a fairly prevalent bleeding disorder, according to the World Federation of Hemophilia. Von Willebrand disease is caused by a deficiency in the protein known as the Von Willebrand factor, which is present in the blood. Rapid FDA approvals of vWD treatment methods and medications, as well as regional marketing approvals, are projected to propel the von Willebrand Disease (vWD) treatment industry forward in the near future. Octapharma's WILATE, a replacement medication for individuals with von Willebrand Disease, was approved by the US Food and Drug Administration (FDA) in 2015. (vWD). VEYVONDI was approved for marketing by the European Medicines Agency (EMA) in 2017 to prevent and treat von Willebrand disease. Shire plc developed VEYVONDI, a replacement therapy that was authorised by the FDA in 2015. In the near future, rapid drug approval is projected to propel the Von Willebrand Disease (vWD) Treatment Market. Because von Willebrand Disease (vWD) is such an uncommon disease, lack of awareness about the disease and its diagnosis is a major restraining factor to its growth. The report has profiled twenty one key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Global Von Willebrand Disease Treatment Market Segment Analysis:

The Global Von Willebrand Disease Treatment Market is segmented on the basis of Treatment Type and Route of Administration.

Based on Treatment, the Desmopressin segment is expected to hold a dominant market share during the forecast period. Desmopressin raises FVIII by stimulating the release of VWF from cells. For patients with type 1 diabetes, which accounts for roughly 70% to 80% of cases, is considered the most preferable treatment approach. Desmopressin is more effective for type 1 and some subtypes of type 2 von Willebrand disease than for the other types, hence it is predicted to grow during the forecast period. Furthermore, the market for von Willebrand disease treatment is expected to grow due to rising health spending and a big patient pool. This drug is offered as a nasal spray or an injection. Anti-fibrinolytic or clot-stabilizing medications are commonly used before or after a surgical treatment or tooth extraction. Adults in the age group of 18 and up are treated with replacement therapies. Based on Route of Administration, the Injection segment is anticipated to grow at a faster pace. The injection segment dominated the global von Willebrand disease treatment market in 2019. During the forecast period, the tendency is expected to continue. The injection market is projected to be driven by factors such as easy, convenient drug administration and the availability of most treatment items in injection form. Global Von Willebrand Disease Treatment Market To know about the Research Methodology :- Request Free Sample Report

Global Von Willebrand Disease Treatment Market Regional Insights:

Global Von Willebrand Disease Treatment Market 1

North America dominates the global market.

Because of the increased desire for progressive treatment options, early adoption of new technology, and an increase in patient assistance programmes, North America is leading the industry. VWD is the most common bleeding disorder, affecting up to 1% of the US population, according to the National Hemophilia Foundation. In 2017, Versiti's BloodCenter of Wisconsin introduced a new assay for a more precise assessment of von Willebrand (VWF) factor activity. Due to rapid marketing approval of vWD therapy medications for marketing in Europe, Europe is predicted to be the second-largest market for von Willebrand Disease (vWD) treatment. The report also helps in understanding Global Von Willebrand Disease Treatment Market dynamics, structure by analyzing the market segments and project the Global Von Willebrand Disease Treatment Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Von Willebrand Disease Treatment Market make the report investor’s guide.

Global Von Willebrand Disease Treatment Market Scope: Inquire before buying

Global Von Willebrand Disease Treatment Market 2

Global Von Willebrand Disease Treatment Market, By Region:

• North America • Europe • South America • MEA • APAC

Global Von Willebrand Disease Treatment Market, Key players:

• Octapharma AG • Grifols, S.A. • Shire plc • Bayer AG • CSL Behring • Pfizer, Inc. • Akorn, Inc. • Ferring B.V. • Kyowa Kirin Co., Ltd • Baxter • Novo Nordisk A/S • Bayer AG • Sanofi • Heritage • Teva Pharmaceutical Industries Ltd • Glenmark Pharmaceuticals Ltd • Bausch Health • Amneal Pharmaceuticals LLC • Sun Pharmaceutical Industries Ltd • Mylan N.V. • Zydus Cadila
1. Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Von Willebrand Disease Treatment Market Size, by Market Value (US$ Mn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2019 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Von Willebrand Disease Treatment Market 3.4. Geographical Snapshot of the Von Willebrand Disease Treatment Market, By Manufacturer share 4. Global Von Willebrand Disease Treatment Market Overview, 2019-2026 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porters Five Forces Analysis 4.1.6.1. Threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. Threat of Substitute Products 4.1.6.5. Intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Global Von Willebrand Disease Treatment Market 5. Supply Side and Demand Side Indicators 6. Global Von Willebrand Disease Treatment Market Analysis and Forecast, 2019-2026 6.1. Global Von Willebrand Disease Treatment Market Size & Y-o-Y Growth Analysis. 7. Global Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 7.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 7.1.1. Desmopressin 7.1.2. Replacement Therapies 7.1.3. Clot-stabilizing Medications 7.1.4. Others 7.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 7.2.1. Oral 7.2.2. Injection 7.2.3. Other 8. Global Von Willebrand Disease Treatment Market Analysis and Forecasts, By Region 8.1. Market Size (Value) Estimates & Forecast By Region, 2019-2026 8.1.1. North America 8.1.2. Europe 8.1.3. Asia-Pacific 8.1.4. Middle East & Africa 8.1.5. South America 9. North America Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 9.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 9.1.1. Desmopressin 9.1.2. Replacement Therapies 9.1.3. Clot-stabilizing Medications 9.1.4. Others 9.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 9.2.1. Oral 9.2.2. Injection 9.2.3. Other 10. North America Von Willebrand Disease Treatment Market Analysis and Forecasts, By Country 10.1. Market Size (Value) Estimates & Forecast By Country, 2019-2026 10.1.1. US 10.1.2. Canada 10.1.3. Mexico 11. U.S. Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 11.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 11.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 12. Canada Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 12.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 12.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 13. Mexico Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 13.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 13.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 14. Europe Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 14.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 14.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 15. Europe Von Willebrand Disease Treatment Market Analysis and Forecasts, By Country 15.1. Market Size (Value) Estimates & Forecast By Country, 2019-2026 15.1.1. U.K 15.1.2. France 15.1.3. Germany 15.1.4. Italy 15.1.5. Spain 15.1.6. Sweden 15.1.7. CIS Countries 15.1.8. Rest of Europe 16. U.K. Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 16.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 16.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 17. France Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 17.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 17.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 18. Germany Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 18.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 18.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 19. Italy Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 19.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 19.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 20. Spain Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 20.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 20.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 21. Sweden Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 21.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 21.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 22. CIS Countries Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 22.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 22.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 23. Rest of Europe Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 23.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 23.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 24. Asia Pacific Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 24.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 24.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 25. Asia Pacific Von Willebrand Disease Treatment Market Analysis and Forecasts, by Country 25.1. Market Size (Value) Estimates & Forecast By Country, 2019-2026 25.1.1. China 25.1.2. India 25.1.3. Japan 25.1.4. South Korea 25.1.5. Australia 25.1.6. ASEAN 25.1.7. Rest of Asia Pacific 26. China Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 26.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 26.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 27. India Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 27.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 27.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 28. Japan Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 28.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 28.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 29. South Korea Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 29.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 29.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 30. Australia Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 30.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 30.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 31. ASEAN Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 31.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 31.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 32. Rest of Asia Pacific Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 32.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 32.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 33. Middle East Africa Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 33.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 33.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 34. Middle East Africa Von Willebrand Disease Treatment Market Analysis and Forecasts, by Country 34.1. Market Size (Value) Estimates & Forecast by Country, 2019-2026 34.1.1. South Africa 34.1.2. GCC Countries 34.1.3. Egypt 34.1.4. Nigeria 34.1.5. Rest of ME&A 35. South Africa Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 35.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 35.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 36. GCC Countries Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 36.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 36.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 37. Egypt Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 37.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 37.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 38. Nigeria Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 38.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 38.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 39. Rest of ME&A Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 39.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 39.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 40. South America Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 40.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 40.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 41. South America Von Willebrand Disease Treatment Market Analysis and Forecasts, by Country 41.1. Market Size (Value) Estimates & Forecast by Country, 2019-2026 41.1.1. Brazil 41.1.2. Argentina 41.1.3. Rest of South America 42. Brazil Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 42.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 42.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 43. Argentina Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 43.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 43.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 44. Rest of South America Von Willebrand Disease Treatment Market Analysis and Forecasts, 2019-2026 44.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2019-2026 44.2. Market Size (Value) Estimates & Forecast By Route of Administration, 2019-2026 45. Competitive Landscape 45.1. Geographic Footprint of Major Players in the Global Von Willebrand Disease Treatment Market 45.2. Competition Matrix 45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Applications and R&D Investment 45.2.2. New Product Launches and Product Enhancements 45.2.3. Market Consolidation 45.2.3.1. M&A by Regions, Investment and Verticals 45.2.3.2. M&A, Forward Integration and Backward Integration 45.2.3.3. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements 45.3. Company Profile : Key Players 45.3.1. Octapharma AG 45.3.1.1. Company Overview 45.3.1.2. Financial Overview 45.3.1.3. Geographic Footprint 45.3.1.4. Product Portfolio 45.3.1.5. Business Strategy 45.3.1.6. Recent Developments 45.3.2. Grifols, S.A. 45.3.3. Shire plc 45.3.4. Bayer AG 45.3.5. CSL Behring 45.3.6. Pfizer, Inc. 45.3.7. Akorn, Inc. 45.3.8. Ferring B.V. 45.3.9. Kyowa Kirin Co., Ltd 45.3.10. Baxter 45.3.11. Novo Nordisk A/S 45.3.12. Bayer AG 45.3.13. Sanofi 45.3.14. Heritage 45.3.15. Teva Pharmaceutical Industries Ltd 45.3.16. Glenmark Pharmaceuticals Ltd 45.3.17. Bausch Health 45.3.18. Amneal Pharmaceuticals LLC 45.3.19. Sun Pharmaceutical Industries Ltd 45.3.20. Mylan N.V. 45.3.21. Zydus Cadila 46. Primary Key Insights

About This Report

Report ID109552
Category Healthcare
Published DateJune 2021
Updated Date
Contact Us